● Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Condition: Breast Cancer, Early Breast Cancer · Sponsor: AstraZeneca

PhasePhase 3

Planned participants5500

Who can joinAll sexes, 18 Years to 130 Years

Healthy volunteersNo

About this study

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

AstraZeneca Breast Cancer Study Locator Service · 1-877-400-4656 · az-bcsl@careboxhealth.com

Always discuss trial participation with your own doctor first.

Locations (798)

Research Site	Dothan, Alabama, United States	Recruiting
Research Site	Phoenix, Arizona, United States	Recruiting
Research Site	Tucson, Arizona, United States	Recruiting
Research Site	Fayetteville, Arkansas, United States	Recruiting
Research Site	Duarte, California, United States	Recruiting
Research Site	Fountain Valley, California, United States	Recruiting
Research Site	Greenbrae, California, United States	Withdrawn
Research Site	Irvine, California, United States	Recruiting
Research Site	La Jolla, California, United States	Recruiting
Research Site	Los Angeles, California, United States	Recruiting
Research Site	Monterey, California, United States	Withdrawn
Research Site	Walnut Creek, California, United States	Recruiting

+ 786 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05952557